-
May 21, 2013
Pfizer's bid to expand its oncology portfolio has suffered a setback with the news that the drugs giant has halted a late-stage trial of inotuzumab ozogamicin in patients with an aggressive form of non-Hodgkin's lymphoma due to futility
-
May 21, 2013
Just as Elan Corp announced a range of transactions "designed to decisively transform and advance the company", long-time suitor Royalty Pharma has popped up again and raised its bid to acquire the Irish drugmaker
-
May 21, 2013
Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals of Norway in a deal valued at $700 million
-
May 21, 2013
Russia, Ukraine and Kazakhstan have recently taken steps to introduce drug reimbursement schemes which, if introduced, could completely change the operating environment for both their innovative drug and generic markets, says new research.
-
May 21, 2013
After a month of speculation, Actavis has announced it is buying Warner Chilcott in a stock-for-stock agreement worth $8.5 billion
-
May 20, 2013
The European Union (EU) is being put at risk because millions of patients in the region cannot afford their medicines, a leading EU politician has warned.
-
May 20, 2013
Takeda Pharmaceutical Co has presented positive late-stage data on a new diabetes compound called fasiglifam
-
May 20, 2013
After announcing plans to restructure its R&D operations in France last year, Sanofi says it will now maintain a research presence in Toulouse for five years, but probably no longe
-
May 20, 2013
An EMA committee has concluded that the benefits of Bayer's acne drug Diane 35 outweigh the risks, "provided that several measures are taken to minimise the risk of thromboembolism"
-
May 20, 2013
Lundbeck and Takeda have presented more positive late-stage data on their recently-filed antidepressant Brintellix